NCT02403674View on ClinicalTrials.gov

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

PHASE3CompletedINTERVENTIONAL

Enrollment

734

Participants

Timeline

Start Date

June 5, 2015

Primary Completion Date

March 20, 2017

Study Completion Date

September 7, 2023

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG

Doravirine, Tenofovir, Lamivudine

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

DRUG

ATRIPLA™

One ATRIPLA™ tablet taken q.d. by mouth

DRUG

Placebo

Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02403674 - Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) | Biotech Hunter | Biotech Hunter